GenoSplice technology is a privately held biotech company leader in transcriptomic data analysis.
The company provides bioinformatics services for international academic laboratories, biotechs and pharmas (e.g., Curie Institute, Pasteur Institute, University of Cambridge, University of Kentucky, Howard Hugues Medical Institute…) and is the Official Service Provider of EURASNET, the European Network of Excellence on Alternative Splicing (gathering 41 research teams from 11 European countries, as well as the USA, Israel and Argentina).
GenoSplice is involved in several international partnerships with industries and academics institutes.
GenoSplice technical developments are focused on development of innovative useful and powerful solutions to take full advantage of new technologies such as high-throughput sequencing. Finally, the company develops R&D projects in collaboration with clinicians in order to identify molecular biomarkers from alternative splicing in cancer.
To facilitate the link between our technologies and the clinical issues, GenoSplice established its operational headquarter within the Saint-Louis Hospital (Paris, France). Our administrative headquarter is at the Genopole® (Evry, France), which is the European "Genetics Valley" dedicated entirely to research in genetics, genomics, post-genomics and related sciences.
According to the Genetics Society, GenoSplice is "demystifying alternative splicing bioinformatics" (Genetics Society News, July 2008).